The Clinical Value of Molecular Subtyping Multiple Myeloma Using Gene Expression Profiling

Using a dataset of 1217 patients with multiple myeloma enrolled in Total Therapies we have examined the impact of novel therapies on molecular and risk subgroups and the clinical value of molecular classification. Bortezomib significantly improved the progression free (PFS) and overall survival (OS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinhold, N, Heuck, C, Rosenthal, A, Thanendrarajan, S, Stein, C, Van Rhee, FV, Zangari, M, Hoering, A, Tian, E, Davies, FE, Barlogie, B, Morgan, GJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740265/
https://www.ncbi.nlm.nih.gov/pubmed/26526987
http://dx.doi.org/10.1038/leu.2015.309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740265/
https://www.ncbi.nlm.nih.gov/pubmed/26526987
http://dx.doi.org/10.1038/leu.2015.309

Ejemplares similares